Alexander W. Casdin Purchases 80,000 Shares of Erasca, Inc. (NASDAQ:ERAS) Stock

Erasca, Inc. (NASDAQ:ERAS) Director Alexander W. Casdin acquired 80,000 shares of the stock in a transaction that occurred on Tuesday, May 21st. The shares were bought at an average price of $2.27 per share, with a total value of $181,600.00. Following the completion of the purchase, the director now owns 573,974 shares in the company, valued at $1,302,920.98. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Erasca Stock Performance

Shares of Erasca stock opened at $2.59 on Friday. The business has a fifty day simple moving average of $2.07 and a 200-day simple moving average of $2.03. Erasca, Inc. has a fifty-two week low of $1.51 and a fifty-two week high of $3.38.

Erasca (NASDAQ:ERAS) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). Sell-side analysts forecast that Erasca, Inc. will post -0.77 EPS for the current year.

Institutional Trading of Erasca

Several institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC lifted its holdings in shares of Erasca by 286.5% in the first quarter. Acadian Asset Management LLC now owns 346,953 shares of the company’s stock valued at $713,000 after buying an additional 257,174 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Erasca by 14.4% during the first quarter. Vanguard Group Inc. now owns 4,338,108 shares of the company’s stock valued at $8,937,000 after purchasing an additional 545,765 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Erasca during the first quarter valued at $216,000. CVI Holdings LLC purchased a new stake in shares of Erasca during the first quarter valued at $3,000,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Erasca by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 29,013 shares of the company’s stock valued at $60,000 after purchasing an additional 11,541 shares during the last quarter. Institutional investors and hedge funds own 67.78% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. HC Wainwright decreased their price target on Erasca from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Monday. The Goldman Sachs Group increased their price target on Erasca from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Finally, Capital One Financial reissued an “overweight” rating and issued a $8.00 price target on shares of Erasca in a research note on Monday, March 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Erasca Company Profile

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.